|
|
|
|
|
|
|
|
|
|
 
|
Pancreas Cancer
News and Archives |
|
A Multitargeted, Metronomic,
and Maximum-Tolerated Dose "Chemo-Switch" Regimen is
Antiangiogenic, Producing Objective Responses and Survival Benefit
in a Mouse Model of Cancer J Clin Oncol. 2004 Dec 21. PMID: 15557593
|
|
 |
|
|
For educational
purposes only; not to be relied upon Please read Pancreatica Disclaimer |
|
 Home | In The News | Links | Donations FAQ | Clinical Trials Database | Research Resources | About Us |
|
|
|
|
|
www.pancreatica.org |